NCT00281554View on ClinicalTrials.gov

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Atrial Fibrillation
Interventions
DRUG

RSD1235

IV

Trial Locations (40)

4001

Berea Durban

4600

Køge

7130

Somerset West

7500

Parow

9301

Bloemfontein

Westdene Bloemfontein

23249

Richmond

30322

Atlanta

35801

Huntsville

48910

Lansing

54449

Marshfield

60453

Oak Lawn

60637

Chicago

78229

San Antonio

78756

Austin

02135

Boston

B8185SAN

Buenos Aires

C1064AAR

Buenos Aires

C1406GZL

Buenos Aires

CP1280

Buenos Aires

CP1437

Buenos Aires

CP3400

Corrientes

Unknown

De Buenos Aires

Rosario

CP4000

Tulunaw

T2N 4N1

Calgary

K1Y 4E9

Ottawa

G2K 4N1

Montreal

H2W 1T8

Montreal

J6V 2H2

Terrebonne

DK-9000

Aalborg

DK-9800

Esbjerg

Hjørring

DK-2650

Hvidovre

DK-2400

København NV

0157

Centurion

SE-205-02

Malmo

SE-431-80

Mölndal

SE-701-85

Örebro

SE-182-88

Stockholm

Sponsors

Collaborators (1)

Advanz Pharma
All Listed Sponsors
collaborator

Advanz Pharma

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY